Device Trial Radar · NCT02774434
Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age
Last checked: Nov 20, 2026Latest source record: Feb 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
464
Actual
Start
Nov 2016
Primary completion
Jun 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Draeger Medical Systems, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 17, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- Who can join
- All sexes, from 24 weeks, up to 40 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Canadian Pediatric Society recently published guidelines to monitor bilirubin levels and as part of standard of care all hospitalized newborns are routinely monitored for the development of high bilirubin or jaundice every 8-12 hours. One device approved and used in both Canada and the United States is the Draeger Jaundice Meter JM-103, a non-invasive medical device. It has been proven to be effective in patients \>35 weeks gestational age. Recently the JM-103 has been upgraded to include a bigger touch screen, greater storage and functionality. The rest of the features of the JM-103 and JM-105 are identical. In order to test the accuracy of the JM-105 neonates from ≥ 24 weeks gestational age who have or have not undergone phototherapy will be prospectively monitored for transcutaneous bilirubin (TcB) using the JM-105. The measurements will be compared to a physician-ordered total serum bilirubin (TSB).
Conditions
- Hyperbilirubinemia
- Neonatal Jaundice
Interventions
JM-105Device
Measurement of TcB via the JM-105 device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Accuracy of TcB measured with the JM-105 device in predicting the Serum Bilirubin measurements performed on blood samplesTime frame: Within 15 minutes of blood sample taking
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Saint Michael's Hospital
Toronto, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Hamilton Health Science Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.